Founded Year

2016

Stage

Series B - II | Alive

Total Raised

$104.6M

Last Raised

$15M | 1 yr ago

About Rally

Rally is a platform where unique, high-value assets are securitized, split into shares, and then offered up as equity investments to users of all income levels. The mission is to democratize alternative asset investing by providing access, liquidity, and transparency to markets that have traditionally only been available to a select few. Utilizing blue-chip classic cars as the initial asset class, Rally Rd. is the first platform allowing investors to create a portfolio of shares in individual automotive assets just like one would purchase stock in a public company.

Rally Headquarter Location

250 Lafayette St 2nd Floor

New York, New York, 10012,

United States

347-952-8058

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Rally's Products & Differentiation

See Rally's products and how their products differentiate from alternatives and competitors

  • Rally App

    Browse & explore investments in a way you never have before. We tell the story behind each of the unique investment-grade collectibles including provenance reports, photos, videos, records & receipts, and history, all through an interactive journey that starts at the item’s creation and ends in the palm of your hand. Like what you see? Make an investment simply & securely with the tap of a button. Each investment entitles you to a percentage of the total value, now and in the future, with the option to sell your shares along the way or hold for the long term.

    Differentiation

    Category defining app with over 300 assets trading and 300k users, across 15+ asset classes, offering deep liquidity & transparent price discovery. 

Research containing Rally

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Rally in 1 CB Insights research brief, most recently on Sep 17, 2021.

Expert Collections containing Rally

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Rally is included in 3 Expert Collections, including Wealth Tech.

W

Wealth Tech

1,793 items

A category of financial technology that is digitizing & streamlining the delivery of wealth management. Included: Startups that offer technology-enabled tools for active and passive wealth management for retail investors and advisors.

F

Fintech 250

500 items

250 of the most promising private companies applying a mix of software and technology to transform the financial services industry.

F

Fintech

7,442 items

US-based companies

Latest Rally News

Celltrion: First Step toward a Virtuous Cycle Rally

Aug 9, 2022

Celltrion: First Step toward a Virtuous Cycle Rally Share Celltrion: First Step toward a Virtuous Cycle Rally By Lee Dong-gun & Won Jae-hee August 9, 2022, 09:35 × The authors are analysts of Shinhan Investment Corp. They can be reached at shawn1225@shinhan.com and jhwon@shinhan.com, respectively. – Ed. 2Q review: Strong results driven by main biz growth & margin gains Celltrion reported consolidated operating profit of KRW199bn (+21.9% YoY, operating margin of 33.4%) on sales of KRW596.1bn (+38.1% YoY) for 2Q22, delivering an earnings surprise vs. our estimates and the market consensus. Adding to top-line growth led by biosimilars, profitability sharply improved in 2Q22 on: 1) increased in-house production of Remsima IV (vs. contract manufacturing through Lonza in 1Q22); 2) visible impact from titer improvement of Truxima; and 3) drop in COGS ratio of COVID-19 test kits along with declines in sales share (1Q22 22% →2Q22 4%) and logistics cost burden (supply of finished products →semi-finished goods). All eyes now on Celltrion Healthcare We believe solid 2Q22 results laid the foundation for a share price rally driven by the virtuous cycle between earnings growth at Celltrion and Celltrion Healthcare. Past data shows that Celltrion Healthcare's earnings results tend to have an impact on the share price performances of both companies. Strong earnings at Celltrion Healthcare backed by brisk sales in overseas markets points to an increase in Celltrion's supply of biosimilars to the company. With Celltrion's 2Q22 results showing visible growth in sales of key biosimilars such as Remsima IV, expectations are growing for a strong earnings report from Celltrion Healthcare on August 16. The outlook is also bright for Remsima SC, with market share growth confirmed in EU5 countries, beneficial effects of switching from infliximab IV presented at EULAR 2022, and positive real data helping to expand marketing efforts. TP raised to KRW270,000 on expectations for a virtuous cycle rally Celltrion's 2Q22 consolidated operating margin of 33.4% squashed investor concerns that rose after the release of 1Q22 results over the company's profitability and growth potential of the biosimilar market. We expect solid earnings to continue through 2H22 on steady top-line growth of biosimilars plus further margin gains. Shipments of Yuflyma, Remsima SC and CT-P43 from 4Q22 for inventory buildup ahead of the US launch in 2H23 should add ample earnings momentum in the near term. With the first step taken toward a virtuous cycle rally of Celltrion and Celltrion Healthcare led by Remsima SC, we maintain BUY for Celltrion and raise our target price to KRW270,000. POPULAR

Rally Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Rally Rank

  • When was Rally founded?

    Rally was founded in 2016.

  • Where is Rally's headquarters?

    Rally's headquarters is located at 250 Lafayette St, New York.

  • What is Rally's latest funding round?

    Rally's latest funding round is Series B - II.

  • How much did Rally raise?

    Rally raised a total of $104.6M.

  • Who are the investors of Rally?

    Investors of Rally include Connor Schell, Thirty Five Ventures, Bill Simmons, Bertelsmann Digital Media Investments, Animal Capital and 23 more.

  • Who are Rally's competitors?

    Competitors of Rally include YieldStreet, Masterworks, Whatnot, Alt, Coinbase and 10 more.

  • What products does Rally offer?

    Rally's products include Rally App.

You May Also Like

V
Vincent

Vincent is a comprehensive search engine for alternative asset investing. The platform aggregates thousands of investment opportunities across real estate, venture capital, private equity, debt, art, collectibles, and more into one easy-to-navigate website. Using Vincent's search engine, investors can create custom searches tailored to fit their interests and portfolio needs.

Alt Logo
Alt

ALT is an investment platform that allows people to buy, sell, and store sports cards. It aims to increase the transparency and liquidity of alternative assets. It enables users to exchange, invest, value, securely store, and authenticate their collectible cards. It was founded in 2020 and is based in San Francisco, California.

Collectable Logo
Collectable

Collectable is an investing platform and community for sports fans that allows users to purchase iconic sports collectibles. It was founded in 2014 and is based in White Plains, New York.

M
Masterworks

Masterworks allows users to purchase and trade shares in historical artworks, by artists such as Monet, Warhol, and Picasso. The company was founded in 2017 and is based in New York, New York.

Mythic Markets Logo
Mythic Markets

Mythic Market is an investing platform to buy, sell and trade fractional shares in rare pop culture collectibles.

Quantbase Logo
Quantbase

Quantbase offers high-risk investing made passive, with index funds for stocks, crypto, NFTs, prediction markets, art, and more. It is a wholly-owned subsidiary of Quantbase Investments, Inc.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.